Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Clinical Trial

Controlled Clinical Trial

Validation Study

Observational Study

Randomized Controlled Trial

Multicenter Study

Publication Year

From

Quick links

Individual year

2021

2020

2018

2017

2015

2012

2011

2007

2003

2002

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Nortropanes""[mesh_terms]

14 Results

Searching titles within these results

Pitfalls and Artifacts of I-Ioflupane SPECT in Parkinsonian Syndromes: A Quality Improvement Teaching Tool.

Cristiane A Tuma Santos, William David Wallace, Sanghun Kim, Vani Vijayakumar

Journal of nuclear medicine technology 2021;49(2):114-119

Free Full Text

Abstract

Optimizing the Diagnosis of Parkinsonian Syndromes With I-Ioflupane Brain SPECT.

Kevin P Banks, Justin G Peacock, Michael N Clemenshaw, Phillip H Kuo

AJR. American journal of roentgenology 2020;213(2):243-253

Full Text

Abstract

I-ioflupane SPET and I-MIBG in the diagnosis of Parkinson's disease and parkinsonian disorders and in the differential diagnosis between Alzheimer's and Lewy's bodies dementias.

Susanna Nuvoli, Barbara Palumbo, Simona Malaspina, Giuseppe Madeddu, Angela Spanu

Hellenic journal of nuclear medicine 2018;21(1):60-68

Free Full Text

Abstract

Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.

Morten Ziebell

Danish medical bulletin 2011;58(5):B4279

Free Full Text

Abstract

Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.

C H Kim, K A Cheon, M-S Koo, Y H Ryu, J D Lee, J W Chang, H S Lee

Neuropsychobiology 2007;55(3-4):156-62

Full Text

Abstract

Calystegines are Potential Urine Biomarkers for Dietary Exposure to Potato Products.

Manfred Beckmann, Amanda J Lloyd, Thomas Wilson, Duarte P M Torres, Ana C L Goios, Naomi D Willis, Laura Lyons, Helen Phillips, John C Mathers, Robert J Nash, Hazel Sharp, John Draper

Molecular nutrition & food research 2021;64(20):e2000515

Full Text

Abstract

Increased microglial activation in patients with Parkinson disease using [F]-DPA714 TSPO PET imaging.

Sonia Lavisse, Sébastien Goutal, Catriona Wimberley, Mattéo Tonietto, Michel Bottlaender, Philippe Gervais, Bertrand Kuhnast, Marie-Anne Peyronneau, Olivier Barret, Julien Lagarde, Marie Sarazin, Philippe Hantraye, Claire Thiriez, Philippe Remy

Parkinsonism & related disorders 2021;82():29-36

Full Text

Abstract

Clinical validity of presynaptic dopaminergic imaging with I-ioflupane and noradrenergic imaging with I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.

Ida Sonni, Osman Ratib, Marina Boccardi, Agnese Picco, Karl Herholz, Flavio Nobili, Andrea Varrone

Neurobiology of aging 2017;52():228-242

Full Text

Abstract

Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.

Margaret R Davis, John R Votaw, J Douglas Bremner, Michael G Byas-Smith, Tracy L Faber, Ronald J Voll, John M Hoffman, Scott T Grafton, Clinton D Kilts, Mark M Goodman

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(6):855-61

Free Full Text

Abstract

Efficiency of I-ioflupane SPECT as the marker of basal ganglia damage in acute methanol poisoning: 6-year prospective study.

Katerina Kotikova, David Zogala, Vaclav Ptacnik, Jiri Trnka, Karel Kupka, Manuela Vaneckova, Zdenek Seidl, Pavel Diblik, Jarmila Heissigerova, Tomas Navratil, Martin Komarc, Ivan Zak, Kamila Polakova, Hana Brozova, Sergey Zakharov

Clinical toxicology (Philadelphia, Pa.) 2021;59(3):235-245

Full Text

Abstract

Biodistribution and dosimetry of ¹²³I-mZIENT: a novel ligand for imaging serotonin transporters.

Alice Nicol, Rajeev Krishnadas, Sue Champion, Gilles Tamagnan, Jeffrey S Stehouwer, Mark M Goodman, Donald M Hadley, Sally L Pimlott

European journal of nuclear medicine and molecular imaging 2012;39(5):786-91

Full Text

Abstract

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.

Lieuwe Appel, My Jonasson, Torsten Danfors, Dag Nyholm, Håkan Askmark, Mark Lubberink, Jens Sörensen

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2015;56(2):234-42

Free Full Text

Abstract

Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.

Andreas R Kupsch, Nin Bajaj, Frederick Weiland, Antonio Tartaglione, Susanne Klutmann, Melanie Buitendyk, Paul Sherwin, Ann Tate, Igor D Grachev

Journal of neurology, neurosurgery, and psychiatry 2012;83(6):620-8

Full Text

Abstract

Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.

Lars H Pinborg, Charlotte Videbaek, Claus Svarer, Stig Yndgaard, Olaf B Paulson, Gitte M Knudsen

European journal of nuclear medicine and molecular imaging 2002;29(5):623-31

Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Nortropanes""[mesh_terms]

Pitfalls and Artifacts of I-Ioflupane SPECT in Parkinsonian Syndromes: A Quality Improvement Teaching Tool.

Optimizing the Diagnosis of Parkinsonian Syndromes With I-Ioflupane Brain SPECT.

I-ioflupane SPET and I-MIBG in the diagnosis of Parkinson's disease and parkinsonian disorders and in the differential diagnosis between Alzheimer's and Lewy's bodies dementias.

Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.

Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.

Calystegines are Potential Urine Biomarkers for Dietary Exposure to Potato Products.

Increased microglial activation in patients with Parkinson disease using [F]-DPA714 TSPO PET imaging.

Clinical validity of presynaptic dopaminergic imaging with I-ioflupane and noradrenergic imaging with I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.

Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.

Efficiency of I-ioflupane SPECT as the marker of basal ganglia damage in acute methanol poisoning: 6-year prospective study.

Biodistribution and dosimetry of ¹²³I-mZIENT: a novel ligand for imaging serotonin transporters.

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.

Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.

Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.

Results for
""Nortropanes""[mesh_terms]